COMPARISON

DSIP vs Linaclotide

5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.

Answer

DSIP is authorised or registered in 0 and Linaclotide in 5 of the 10 registers read. DSIP: No trial states a phase. Linaclotide: highest phase Phase 3 (1 phase 3 trial, 0 with posted results). 0 registered trials include both.

States no view on which is preferable, safer or more effective. Not medical advice.

DSIPLinaclotide
Registered trials
differs
1
clinicaltrials.gov · 2026-10-03
62
clinicaltrials.gov · 2026-10-03
FDA label
differs
Not checked
no record of "fdaLabel" for dsip
FDA-approved: Linzess
openfda · 2026-10-03T17:23:44.062Z
EU authorisation
differs
Nothing on record
ema read 2026-08-31
Authorised
ema · 2026-10-03
EU authorised on
differs
Not checked
no record of "authorisedOn" for dsip
2012-11-26
ema · 2026-10-03
ATC code
differs
Not checked
no record of "atcCode" for dsip
A06AX04
ema · 2026-10-03

SIDE EFFECTS

Most common side effects, each beside its own placebo

Side effectDSIPplaceboLinaclotideplacebo
Diarrhea--14.0%4.6%

Trial register DSIP: 0 placebo-controlled trials; Linaclotide: 14. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. DSIP side effects · Linaclotide side effects

LEGAL STATUS

Approval in each country read

CountryDSIPLinaclotideRegister
United StatesNot on the registerFDA-approvedRegulator FDA
European UnionNot on the registerAuthorisedRegulator EMA
United KingdomNot on the registerAuthorisedRegulator MHRA
CanadaNot on the registerAuthorisedRegulator Health Canada
AustraliaStatus unknownStatus unknown TGA
SwitzerlandNot on the registerAuthorisedRegulator Swissmedic
BrazilNot on the registerNot on the registerRegulator ANVISA
SerbiaNot on the registerNot on the registerRegulator ALIMS
SingaporeNot on the registerNot on the registerRegulator HSA
TurkeyNot on the registerNot on the registerRegulator TITCK

Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.